It's only Tuesday. See where we are by close Friday. It's not a small deal, the growth potential towards possible FDA approval for Brilacidin for IBD and throughout the EU (world wide actually) can be extraordinary. And this is only one indicator. Full market penetration, a 6% royalty will be quite impressive imo.


Bigger fish are swirling imo. A little OTC validated by a big pharma.

This is huge boys and girls. Give them a chance to do their dd.